IP in the Pharmaceutical Industry — Patents, Data Exclusivity and Compulsory Licensing
India's pharmaceutical sector is unique in the global IP landscape. The country is the world's pharmacy — supplying affordable generic medicines globally — while also being a growing hub of pharmaceutical innovation. The tension between IP protection and access to medicines makes pharma IP in India particularly complex.
India's Unique Position — TRIPS and Section 3(d)
India joined the TRIPS agreement in 1995 and was required to extend patent protection to pharmaceutical products from 2005. Before that, India only allowed process patents — meaning the same drug could be made by a different process and sold as a generic.
When implementing product patents, India introduced Section 3(d) of the Patents Act — a provision that prevents "evergreening" — the practice of making minor modifications to existing drugs to extend patent protection without genuine innovation. A new form of a known substance is not patentable unless it shows significantly enhanced efficacy.
Section 3(d) in Action: The famous Novartis vs Union of India case (2013) saw the Supreme Court reject a patent for Gleevec (imatinib mesylate) citing Section 3(d), ruling that the beta crystalline form was not significantly more efficacious than the known compound. This judgment reaffirmed India's commitment to preventing evergreening.
What Can be Patented in Indian Pharma?
- Novel chemical entities (NCEs) — genuinely new drug molecules
- New pharmaceutical compositions showing enhanced efficacy
- Novel drug delivery systems with technical innovation
- New processes for making known or new drugs
- Novel medical devices and diagnostic tools
- Biotechnology innovations — new biological sequences, methods
Compulsory Licensing — When Public Health Overrides IP
Under Section 84 of the Patents Act, compulsory licensing can be granted when: the reasonable requirements of the public are not met, the patented invention is not available at a reasonably affordable price, or the invention is not worked in India to an adequate extent.
India's only compulsory licence to date was granted in 2012 for sorafenib (cancer drug) to Natco Pharma, allowing it to make a generic version of Bayer's Nexavar at a fraction of the price. This remains a landmark case in global IP law.
Trademark in Pharma — Brand vs Generic
In pharmaceuticals, trademarks are crucial. Branded drugs command significant price premiums over generics. A strong brand trademark protects the premium product even after patent expiry. Many pharma companies register trademarks for drug names, company names and logos.
Note: Drug names must be approved by the Central Drugs Standard Control Organisation (CDSCO) and cannot be confusingly similar to existing approved drug names — adding an additional layer of clearance before trademark filing.
Need Help Protecting Your Innovation?
ISERDIndia's registered Patent & Trademark Agents offer a free initial consultation.
Get Free Consultation →